Association between the major histocompatibility complex and clinical response to infliximab therapy in patients with Behçet uveitis

Kuroyanagi, Kana; Sakai, Tsutomu; Kohno, Hideo; Okano, Kiichiro; Akiyama, Goichi; Aoyagi, Ranko; Inaba, Mayumi; Tsuneoka, Hiroshi

doi:10.1007/s10384-015-0404-2

Cited by 7 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HLA-A*26 carriers have been reported to have a higher risk of iridocyclitis and retinochoroiditis, which is more prominent in men. 29 Kuroyanagi et al 41 However, a study evaluating the complete HLA panel and its correlation with clinical findings in an acceptable number of well-characterized BD patients, such as ours, has not yet been performed. We found differences in allelic distribution based on ethnicity, which is supported by ancestry testing in specific populations.…”

Section: Discussionmentioning

confidence: 91%

“…HLA-A*26 carriers have been reported to have a higher risk of iridocyclitis and retinochoroiditis, which is more prominent in men 29 . Kuroyanagi et al 41 demonstrated an association between HLA-A*26 and the clinical response to infliximab therapy in Japanese patients with BD uveitis and concluded that patients who presented with HLA-A*26:01 had the best visual acuity after treatment. Recently, Su et al 42 identified HLA-A*26 as a new risk allele for uveitis in a Chinese population with BD.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

HLA Alleles in a Behçet Disease Multiethnic Population With and Without Ophthalmic Manifestations

de Andrade,

Porto,

Gomes Ochtrop

et al. 2023

J Clin Rheumatol

View full text Add to dashboard Cite

Objective The aim of this study was to analyze HLA alleles in patients with Behçet disease (BD) and their correlation with ophthalmic manifestations (OMs) in a multiethnic Brazilian population. Methods This case-control study compared 72 BD patients with or without OM who underwent a thorough ophthalmologic evaluation, including best-corrected visual acuity, bino-ophthalmoscopy, and HLA analysis, with 144 matched healthy controls. Fluorescein angiography was also performed in the patients with BD and OM. HLA class I (A, B, and C) and II (DRB1, DQB1, and DQA1) typing were performed using PCR-SSO. Results Of 72 patients with BD, 42 (58%) had OM. The HLA-B*51 and -A*26 alleles were more frequent in patients with BD than in controls (23.6% vs 14.6% and 12.5% vs 4.3%, respectively), but could not differentiate OM risk. The HLA alleles of BD patients that differentiated those with and without OM were HLA-B*15 (40.5% vs 20.7%; odds ratio [OR], 2.59; p = 0.0059), HLA-C*02 (33.3% vs 13.4%; OR, 3.20; p = 0.0024), and HLA-DQB1*03 (64.3% vs 45.7%, p = 0.017), whereas HLA-A*03 (0.0% vs 13.3%, p = 0.006) and HLA-DRB1*15 (4.8% vs 19.5%; OR, 0.21; p = 0.0121) were protective against OM. Conclusions In this study of a Brazilian multiethnic BD population, alleles were similar between groups of BD patients with and without OM. We described HLA-B*15, -C*02, and -DQB1*03 as risk factors and -A*03 and -DRB1*15 as protective factors for OM in BD, which could function as biomarkers for predicting disease phenotypes.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

HLA Alleles in a Behçet Disease Multiethnic Population With and Without Ophthalmic Manifestations

de Andrade,

Porto,

Gomes Ochtrop

et al. 2023

J Clin Rheumatol

View full text Add to dashboard Cite

show abstract

“…A new generation of biological compounds that inhibit T cell activation such as monoclonal antibodies and recombinant forms of natural inhibitory molecules have emerged (36,37). For example, IFX is validated for the treatment of refractory ocular Behçet's disease (1,38,39). Adalimumab (ADA), which is a recombinant human immunoglobulin G1 monoclonal antibody to TNF-α, has also been validated for the treatment of patients with NIU in the United States and in Japan.…”

Section: Non-infectious Uveitis (Niu) Human Non-infectious Uveitismentioning

confidence: 99%

New Insights Into Immunological Therapy for Retinal Disorders

et al. 2020

View full text Add to dashboard Cite

In the twentieth century, a conspicuous lack of effective treatment strategies existed for managing several retinal disorders, including age-related macular degeneration; diabetic retinopathy (DR); retinopathy of prematurity (ROP); retinitis pigmentosa (RP); uveitis, including Behçet's disease; and vitreoretinal lymphoma (VRL). However, in the first decade of this century, advances in biomedicine have provided new treatment strategies in the field of ophthalmology, particularly biologics that target vascular endothelial growth factor or tumor necrosis factor (TNF)-α. Furthermore, clinical trials on gene therapy specifically for patients with autosomal recessive or X-linked RP have commenced. The overall survival rates of patients with VRL have improved, owing to earlier diagnoses and better treatment strategies. However, some unresolved problems remain such as primary or secondary non-response to biologics or chemotherapy, and the lack of adequate strategies for treating most RP patients. In this review, we provide an overview of the immunological mechanisms of the eye under normal conditions and in several retinal disorders, including uveitis, DR, ROP, RP, and VRL. In addition, we discuss recent studies that describe the inflammatory responses that occur during the course of these retinal disorders to provide new insights into their diagnosis and treatment.

show abstract

Laser flare-cell photometer: principle and significance in clinical and basic ophthalmology

Sawa

2016

Jpn J Ophthalmol

View full text Add to dashboard Cite

A slit-lamp examination is an indispensable and essential clinical evaluation method in ophthalmology, but, it is qualitative subjective. To complement its weaknesses in making a quantitative evaluation of flare intensity and number of cells in the aqueous humor in the eye, we invented the laser flare-cell photometer in 1988. The instrument enables a non-invasive quantitative evaluation of flare intensity and number of cells in the aqueous with good accuracy and repeatability as well as maneuverability equal to slit-lamp microscopy. The instrument can elucidate the pathophysiology in the blood-aqueous barrier (BAB) function in a variety of ocular disorders. The accuracy of the instrument makes it possible to investigate not only the pathophysiology of intraocular disorders but also the effects of various drugs and surgical procedures in BAB. The instrument does not only lighten the burden on patients in clinical examinations and study but it also helps minimize the sacrifice of experimental animals and improves the reliability of the results by minimizing inter-individual variations through its good repeatability. Here I shall relate how the instrument has been applied to clinical and basic studies in ophthalmology and what novel knowledge its application contributed to pathophysiology in ophthalmology.

show abstract

Association between the major histocompatibility complex and clinical response to infliximab therapy in patients with Behçet uveitis

Cited by 7 publications

References 16 publications

HLA Alleles in a Behçet Disease Multiethnic Population With and Without Ophthalmic Manifestations

HLA Alleles in a Behçet Disease Multiethnic Population With and Without Ophthalmic Manifestations

New Insights Into Immunological Therapy for Retinal Disorders

Laser flare-cell photometer: principle and significance in clinical and basic ophthalmology

Contact Info

Product

Resources

About